| All Releases |
|---|
 |
Alseres Shares Begin Trading on the Pink Sheets OTC Market
May 7, 2009
|
13.1 KB |
|
| |
HOPKINTON, Mass., May 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; Alseres) announced today that effective on Friday, May 8, 2009 trading in its shares on the NASDAQ Capital Market will be suspended. Effective at the same time, Alseres common stock will be available for quotation on the Pin...
|
|
Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
Apr 30, 2009
|
12.8 KB |
|
| |
HOPKINTON, Mass., April 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE; the Company) announced today that on April 24, 2009 it entered into an Amendment to License Agreement (Amendment) with BioAxone Therapeutic, Inc. (BioAxone), pursuant to which the license agreement between the Company and ...
|
|
Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
Apr 14, 2009
|
11.8 KB |
|
| |
HOPKINTON, Mass., April 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced that on April 9, 2009 it received a NASDAQ Staff Determination indicating that the Company has not regained compliance with the minimum $35 million market value of listed securities requirement set forth in NASDA...
|
|
Alseres Receives Special Protocol Assessment Agreement from FDA for Phase III Trial of Altropane
Apr 6, 2009
|
14.1 KB |
|
| |
HOPKINTON, Mass., April 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced today that it has reached agreement with the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the Phase III protocol of Alseres' Altropane(R) Molecular Imaging Agent to...
|
|
Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Mar 31, 2009
|
11.0 KB |
|
| |
HOPKINTON, Mass., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the report of the Company's independent registered public accounting firm regarding the Company's 2008 financial statements contained an explanatory paragraph regarding the Company's ability to continu...
|
|
Alseres Pharmaceuticals, Inc. Reports 2008 Results
Mar 26, 2009
|
9.3 KB |
|
| |
HOPKINTON, Mass., March 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that they will host a conference call on Wednesday, April 1st at 9:00am EDT to review 2008 results.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
To access the conference call, please ...
|
|
Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
Feb 27, 2009
|
12.5 KB |
|
| |
HOPKINTON, Mass., Feb 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that on February 24, 2009 it entered into a securities purchase agreement (the "Agreement") with Cato Holding Company (d/b/a Cato BioVentures) for the private placement of 200,000 shares of common stock of t...
|
|
Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Feb 3, 2009
|
16.0 KB |
|
| |
HOPKINTON, Mass., Feb 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), announced today that it has completed enrollment in the first stage of the Altropane Parkinson's or Essential Tremor (POET-2) Phase III clinical program. The objective of the first part of the program was to acquire the se...
|
|
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Jan 13, 2009
|
13.0 KB |
|
| |
HOPKINTON, Mass., Jan 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that on January 8, 2009 it entered into a securities purchase agreement (the "Agreement") with Robert Gipson for the private placement of 1,000,000 shares of common stock of the Company at a purchase price o...
|
|
Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
Jan 12, 2009
|
12.7 KB |
|
| |
HOPKINTON, Mass., Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. today announced that on January 8, 2009, it received notice from the NASDAQ Stock Market ("NASDAQ") that for the last 10 consecutive trading days, the market value of its listed securities has been below the minimum $35 million requirement...
|
|
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Nov 21, 2008
|
12.3 KB |
|
| |
HOPKINTON, Mass., Nov 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres
Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that it has entered into
a securities purchase agreement with Robert Gipson for the private placement
of 543,478 shares of common stock of the Company, together with warrants to
purchase 543,478 addition...
|
|
Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Nov 13, 2008
|
15.5 KB |
|
| |
HOPKINTON, Mass., Nov 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended September 30, 2008 and provides further information for fiscal year 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
"We are...
|
|
Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
Nov 7, 2008
|
12.1 KB |
|
| |
HOPKINTON, Mass., Nov 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that they will host a conference call on Friday, November 14th, 2008 at 9:00am ET to review the third quarter ending September 30, 2008 and discuss other matters related to the Company.
(Logo: http://www....
|
|
Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Nov 5, 2008
|
10.6 KB |
|
| |
HOPKINTON, Mass., Nov 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Peter Savas, Chairman and CEO of Alseres Pharmaceuticals, Inc., will present Monday, November 10th at 2:00pm ET at Rodman & Renshaw Annual Healthcare Conference at the New York Palace Hotel in New York p...
|
|
The European Commission Grants Orphan Drug Designation to Alseres Pharmaceuticals' Spinal Cord Injury Treatment, Cethrin(R)
Sep 18, 2008
|
13.5 KB |
|
| |
HOPKINTON, Mass., Sept 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE) announced today that Cethrin has been granted designation as an orphan medicinal product for the treatment of traumatic spinal cord injury (SCI) by the European Commission. The European Commission's decision was adopted on...
|
|
Alseres Pharmaceuticals Announces Preclinical Study Results Demonstrating that Rho Inhibitors Could Be Useful in Promoting Bone Healing
Aug 28, 2008
|
12.3 KB |
|
| |
HOPKINTON, Mass., Aug 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced that data from preclinical studies of the Company's regenerative therapy candidate, ALSE-100, were presented at the Australian and New Zealand Bone and Mineral Society Annual Conference, August 28-30, 2008 in Mel...
|
|
Alseres Pharmaceuticals Consolidates Its Offices and Moves into New Headquarters
Aug 19, 2008
|
13.0 KB |
|
| |
HOPKINTON, Mass., Aug 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that following the expiration of its current leases it will consolidate its offices to a new headquarters in Hopkinton, Massachusetts.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
...
|
|
Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Aug 13, 2008
|
16.6 KB |
|
| |
HOPKINTON, Mass., Aug 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended June 30, 2008 and provides further information for fiscal year 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
"Alseres mad...
|
|
Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
Aug 7, 2008
|
12.1 KB |
|
| |
HOPKINTON, Mass., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, August 14th, 2008 at 9:00am EDT to review the second quarter ending June 30, 2008 and discuss other matters related to the Company.
(Logo: http://www.ne...
|
|
Alseres Pharmaceuticals, Inc. Raises $5 Million
Jun 30, 2008
|
12.4 KB |
|
| |
HOPKINTON, Mass., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- On June 25, 2008, Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), a biopharmaceuticals company engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system, entered a into Convertible Promissory Note Purchase Ag...
|
|
|
